thalidomide has been researched along with Feuerstein-Mims Syndrome in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ossorio-García, L | 1 |
Jiménez-Gallo, D | 1 |
Collantes-Rodríguez, C | 1 |
Báez-Perea, JM | 1 |
Linares-Barrios, M | 1 |
1 other study available for thalidomide and Feuerstein-Mims Syndrome
Article | Year |
---|---|
Treatment of inflammatory linear verrucous epidermal nevus pruritus with thalidomide.
Topics: Adult; Antipruritics; Humans; Male; Nevus, Sebaceous of Jadassohn; Pruritus; Skin Neoplasms; Thalido | 2018 |